当前位置: 首页 >> 检索结果
661. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
作者: Zhewen Xiong.;Stephen Lam Chan.;Jingying Zhou.;Joaquim S L Vong.;Tsz Tung Kwong.;Xuezhen Zeng.;Haoran Wu.;Jianquan Cao.;Yalin Tu.;Yu Feng.;Weiqin Yang.;Patrick Pak-Chun Wong.;Willis Wai-Yiu Si-Tou.;Xiaoyu Liu.;Jing Wang.;Wenshu Tang.;Zhixian Liang.;Jiahuan Lu.;Ka Man Li.;Jie-Ting Low.;Michael Wing-Yan Chan.;Howard H W Leung.;Anthony W H Chan.;Ka-Fai To.;Kevin Yuk-Lap Yip.;Yuk Ming Dennis Lo.;Joseph Jao-Yiu Sung.;Alfred Sze-Lok Cheng.
来源: Gut. 2023年72卷9期1758-1773页
Therapy-induced tumour microenvironment (TME) remodelling poses a major hurdle for cancer cure. As the majority of patients with hepatocellular carcinoma (HCC) exhibits primary or acquired resistance to antiprogrammed cell death (ligand)-1 (anti-PD-[L]1) therapies, we aimed to investigate the mechanisms underlying tumour adaptation to immune-checkpoint targeting.
662. Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.
作者: Jianhui Zhao.;Jie Chen.;Yuhao Sun.;Shuai Yuan.;Judith Wellens.;Rahul Kalla.;Evropi Theodoratou.;Xue Li.;Jack Satsangi.
来源: Gut. 2024年73卷5期878-879页 663. Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature.
作者: Anna Ralser.;Alisa Dietl.;Sebastian Jarosch.;Veronika Engelsberger.;Andreas Wanisch.;Klaus Peter Janssen.;Moritz Middelhoff.;Michael Vieth.;Michael Quante.;Dirk Haller.;Dirk H Busch.;Li Deng.;Raquel Mejías-Luque.;Markus Gerhard.
来源: Gut. 2023年72卷7期1258-1270页
Helicobacter pylori infection is the most prevalent bacterial infection worldwide. Besides being the most important risk factor for gastric cancer development, epidemiological data show that infected individuals harbour a nearly twofold increased risk to develop colorectal cancer (CRC). However, a direct causal and functional connection between H. pylori infection and colon cancer is lacking.
666. MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
作者: Huiying Lu.;Cui Zhang.;Wei Wu.;Huimin Chen.;Ritian Lin.;Ruicong Sun.;Xiang Gao.;Gengfeng Li.;Qiong He.;Han Gao.;Xiaohan Wu.;Jian Lin.;Ruixin Zhu.;Jianli Niu.;Pappachan E Kolattukudy.;Zhanju Liu.
来源: Gut. 2023年72卷5期882-895页
Monocyte chemotactic protein-1-induced protein 1 (MCPIP1) is highly expressed in inflamed mucosa of inflammatory bowel disease (IBD) and negatively regulates immune response, while the underlying mechanisms regulating mucosal macrophage functions remain unknown. Here, we investigated the roles of MCPIP1 in modulating the differentiation and functions of intestinal macrophages in the pathogenesis of IBD.
667. Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials.
作者: Po-Yueh Chen.;Feng-Pai Tsai.;Mei-Jyh Chen.;Hsin-Yi Yang.;Ming-Shiang Wu.;Jyh-Ming Liou.
来源: Gut. 2024年73卷5期872-874页 668. Mixed-donor faecal microbiota transplantation was associated with increased butyrate-producing bacteria for obesity.
作者: Zhilu Xu.;Joyce Wing Yan Mak.;Yu Lin.;Keli Yang.;Qin Liu.;Fen Zhang.;Louis Lau.;Whitney Tang.;Jessica Yl Ching.;Hein M Tun.;Paul Chan.;Francis K L Chan.;Siew C Ng.
来源: Gut. 2024年73卷5期875-878页 669. It is better to light a candle than to curse the darkness: single-cell transcriptomics sheds new light on pancreas biology and disease.
作者: Amelia T Cephas.;William L Hwang.;Anirban Maitra.;Oren Parnas.;Kathleen E DelGiorno.
来源: Gut. 2023年72卷6期1211-1219页
Recent advances in single-cell RNA sequencing and bioinformatics have drastically increased our ability to interrogate the cellular composition of traditionally difficult to study organs, such as the pancreas. With the advent of these technologies and approaches, the field has grown, in just a few years, from profiling pancreas disease states to identifying molecular mechanisms of therapy resistance in pancreatic ductal adenocarcinoma, a particularly deadly cancer. Single-cell transcriptomics and related spatial approaches have identified previously undescribed epithelial and stromal cell types and states, how these populations change with disease progression, and potential mechanisms of action which will serve as the basis for designing new therapeutic strategies. Here, we review the recent literature on how single-cell transcriptomic approaches have changed our understanding of pancreas biology and disease progression.
672. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
作者: Marta Canel.;Aleksandra Dominika Sławińska.;David W Lonergan.;Ashwin Adrian Kallor.;Rosie Upstill-Goddard.;Catherine Davidson.;Alex von Kriegsheim.;Andrew V Biankin.;Adam Byron.;Javier Alfaro.;Alan Serrels.
来源: Gut. 2023年73卷1期131-155页
Immunotherapy for the treatment of pancreatic ductal adenocarcinoma (PDAC) has shown limited efficacy. Poor CD8 T-cell infiltration, low neoantigen load and a highly immunosuppressive tumour microenvironment contribute to this lack of response. Here, we aimed to further investigate the immunoregulatory function of focal adhesion kinase (FAK) in PDAC, with specific emphasis on regulation of the type-II interferon response that is critical in promoting T-cell tumour recognition and effective immunosurveillance.
673. NNMT enriches for AQP5+ cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma.
作者: Zhangding Wang.;Qiang Wang.;Chen Chen.;Xiaoya Zhao.;Honggang Wang.;Lei Xu.;Yao Fu.;Guang Huang.;Mengmeng Li.;Jiawen Xu.;Qianyi Zhang.;Bo Wang.;Guifang Xu.;Lei Wang.;Xiaoping Zou.;Shouyu Wang.
来源: Gut. 2023年73卷1期63-77页
Early gastric cardia adenocarcinoma (EGCA) is a highly heterogeneous cancer, and the understanding of its classification and malignant progression is limited. This study explored the cellular and molecular heterogeneity in EGCA using single-cell RNA sequencing (scRNA-seq).
674. Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
作者: Álvaro Giráldez-Gallego.;Elisa Del Pilar Rodríguez-Seguel.;Raquel Valencia-Martín.;Áurea Morillo-García.;Celia Salamanca-Rivera.;Ricardo Ruiz-Pérez.;María Cuaresma-Duque.;Clara Rosso-Fernández.;María Teresa Ferrer-Ríos.;José Manuel Sousa-Martín.;Juan Manuel Praena-Fernández.;Trinidad Desongles-Corrales.;Aitana Rodríguez-Pérez.;Francisco Camino-Durán.;Antonia Gasch-Illescas.;Javier Ampuero-Herrojo.;Juan Manuel Pascasio-Acevedo.
来源: Gut. 2023年73卷1期166-174页
We aimed to compare the response rates between two different hepatitis B virus vaccination schedules for cirrhotic subjects who were non-responders to the first three 40 µg doses (month 0-1-2), and identify factors associated with the final response.
675. Faecal metabolome and its determinants in inflammatory bowel disease.
作者: Arnau Vich Vila.;Shixian Hu.;Sergio Andreu-Sánchez.;Valerie Collij.;Bernadien H Jansen.;Hannah E Augustijn.;Laura A Bolte.;Renate A A A Ruigrok.;Galeb Abu-Ali.;Cosmas Giallourakis.;Jessica Schneider.;John Parkinson.;Amal Al-Garawi.;Alexandra Zhernakova.;Ranko Gacesa.;Jingyuan Fu.;Rinse K Weersma.
来源: Gut. 2023年72卷8期1472-1485页
Inflammatory bowel disease (IBD) is a multifactorial immune-mediated inflammatory disease of the intestine, comprising Crohn's disease and ulcerative colitis. By characterising metabolites in faeces, combined with faecal metagenomics, host genetics and clinical characteristics, we aimed to unravel metabolic alterations in IBD.
676. A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut.
作者: Sidharth P Mishra.;Bo Wang.;Shalini Jain.;Jingzhong Ding.;Jared Rejeski.;Cristina M Furdui.;Dalane W Kitzman.;Subhash Taraphder.;Christian Brechot.;Ambuj Kumar.;Hariom Yadav.
来源: Gut. 2023年72卷10期1848-1865页
Ample evidence exists for the role of abnormal gut microbiota composition and increased gut permeability ('leaky gut') in chronic inflammation that commonly co-occurs in the gut in both obesity and diabetes, yet the detailed mechanisms involved in this process have remained elusive.
679. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.
作者: Robyn Laube.;Christian P Selinger.;Cynthia H Seow.;Britt Christensen.;Emma Flanagan.;Debra Kennedy.;Reme Mountifield.;Sean Seeho.;Antonia Shand.;Astrid-Jane Williams.;Rupert W Leong.
来源: Gut. 2023年72卷6期1040-1053页
Because pregnancy outcomes tend to be worse in women with inflammatory bowel disease (IBD) than in those without, we aimed to update consensus statements that guide the clinical management of pregnancy in patients with IBD.
|